The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,823,351 | -214,239 |
| Forgiveness of unrelated vendor payables | 0 | 2,142,297 |
| Depreciation | 542 | 743 |
| Change in fair value of deferred underwriting fee - common stock payable | 560,000 | -756,000 |
| Change in the fair value of warrant liabilities | -76,871 | 116,894 |
| Issuance of common stock in connection with the surrender of warrants | -1,740,000 | - |
| Due from related party, current | 0 | 3,427,000 |
| Prepaid and other current assets | 34,782 | -43,442 |
| Accounts payable and accrued expenses | -2,014,999 | -2,043,405 |
| Accrued interest, related parties | -19,052 | -177,800 |
| Accrued maintenance fee | - | 360,000 |
| Due to research and development partner | - | 1,782,297 |
| Due to related party | 7,500 | -101,500 |
| Net cash used in operating activities | -600,612 | -8,975,859 |
| Loans to iris acquisition corp | 0 | 775,000 |
| Purchases of property and equipment | 13,108 | - |
| Net cash used in investing activities | -13,108 | -775,000 |
| Gross proceeds from issuance of common stock for pipe investment | 0 | 10,556,500 |
| Payment of transaction costs | 0 | 2,563,738 |
| Proceeds from issuance of short-term debt, related party | 0 | 4,340,000 |
| Repayment of short-term debt, related party | 0 | 1,300,000 |
| Net cash provided by financing activities | 0 | 11,032,762 |
| Net change in cash | -613,720 | 1,281,903 |
| Cash and cash equivalents at beginning of period | 1,338,222 | 56,319 |
| Cash and cash equivalents at end of period | 724,502 | 1,338,222 |
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)